OBJECTIVE: To learn if Hispanic people with type 2 diabetes have excess incidence and/or progression of diabetic retinopathy and to explore the association of risk factors with diabetic retinopathy. RESEARCH DESIGN AND METHODS: There were 244 subjects with type 2 diabetes (65.3% Hispanic) with at least one follow-up visit between 1984 and 1992 examined for the development of retinopathy over a median of 4.8 years (range 2.0-6.6 years). Stereo fundus photos were graded by the University of Wisconsin Reading Center. RESULTS: Of the 169 subjects without retinopathy at baseline, 47 developed some retinopathy, an incidence rate of 63.7 per 1,000 person-years (PY), or a 4-year cumulative incidence of 22.5%. The Hispanic incidence rate was 58.3/1,000 PY (95% CI: 39.4-83.3), which was lower than among non-Hispanic whites, 76.1/1,000 PY (44.3-121.9). Progression occurred in 24 of the 75 subjects with retinopathy at baseline, a 4-year cumulative rate of 24.1%. Logistic regression showed that insulin treatment was associated with higher risk of any retinopathy (odds ratio [OR] = 8.45, 2.65-26.97), and both systolic blood pressure (odds ratio [OR] = 1.58, 0.99-2.52) and total GHb (OR = 1.46, 0.99-2.17) nearly attained statistical significance. After adjustment for multiple potential risk factors, the Hispanic/non-Hispanic white OR was 0.66 (0.28-1.57). CONCLUSIONS: No excess risk for incident retinopathy was found among Hispanic compared with non-Hispanic white subjects in this population. These results are consistent with our previously reported prevalence data from the same population but differ from reports of excess prevalence among Texas Hispanics. No other Hispanic incidence data are available to assist in reconciling this difference.
OBJECTIVE: To learn if Hispanic people with type 2 diabetes have excess incidence and/or progression of diabetic retinopathy and to explore the association of risk factors with diabetic retinopathy. RESEARCH DESIGN AND METHODS: There were 244 subjects with type 2 diabetes (65.3% Hispanic) with at least one follow-up visit between 1984 and 1992 examined for the development of retinopathy over a median of 4.8 years (range 2.0-6.6 years). Stereo fundus photos were graded by the University of Wisconsin Reading Center. RESULTS: Of the 169 subjects without retinopathy at baseline, 47 developed some retinopathy, an incidence rate of 63.7 per 1,000 person-years (PY), or a 4-year cumulative incidence of 22.5%. The Hispanic incidence rate was 58.3/1,000 PY (95% CI: 39.4-83.3), which was lower than among non-Hispanic whites, 76.1/1,000 PY (44.3-121.9). Progression occurred in 24 of the 75 subjects with retinopathy at baseline, a 4-year cumulative rate of 24.1%. Logistic regression showed that insulin treatment was associated with higher risk of any retinopathy (odds ratio [OR] = 8.45, 2.65-26.97), and both systolic blood pressure (odds ratio [OR] = 1.58, 0.99-2.52) and total GHb (OR = 1.46, 0.99-2.17) nearly attained statistical significance. After adjustment for multiple potential risk factors, the Hispanic/non-Hispanic white OR was 0.66 (0.28-1.57). CONCLUSIONS: No excess risk for incident retinopathy was found among Hispanic compared with non-Hispanic white subjects in this population. These results are consistent with our previously reported prevalence data from the same population but differ from reports of excess prevalence among Texas Hispanics. No other Hispanic incidence data are available to assist in reconciling this difference.
Authors: Ethan Paddock; Helen C Looker; Paolo Piaggi; William C Knowler; Jonathan Krakoff; Douglas C Chang Journal: Diabetes Care Date: 2018-04-05 Impact factor: 19.112
Authors: Rohit Varma; Farzana Choudhury; Ronald Klein; Jessica Chung; Mina Torres; Stanley P Azen Journal: Am J Ophthalmol Date: 2010-02-10 Impact factor: 5.258
Authors: Bashira A Charles; Yvette P Conley; Guanjie Chen; Rachel G Miller; Janice S Dorman; Michael B Gorin; Robert E Ferrell; Susan M Sereika; Charles N Rotimi; Trevor J Orchard Journal: Ophthalmic Res Date: 2010-11-19 Impact factor: 2.892
Authors: Nedal H Arar; Barry I Freedman; Sharon G Adler; Sudha K Iyengar; Emily Y Chew; Mathew D Davis; Scott G Satko; Donald W Bowden; Ravi Duggirala; Robert C Elston; Xiuxing Guo; Robert L Hanson; Robert P Igo; Eli Ipp; Paul L Kimmel; William C Knowler; Julio Molineros; Robert G Nelson; Madeleine V Pahl; Shannon R E Quade; Rebekah S Rasooly; Jerome I Rotter; Mohammed F Saad; Marina Scavini; Jeffrey R Schelling; John R Sedor; Vallabh O Shah; Philip G Zager; Hanna E Abboud Journal: Invest Ophthalmol Vis Sci Date: 2008-09 Impact factor: 4.799
Authors: William S Gange; Jennifer Lopez; Benjamin Y Xu; Khristina Lung; Seth A Seabury; Brian C Toy Journal: Diabetes Care Date: 2021-09-02 Impact factor: 19.112
Authors: Miguel Á Salinero-Fort; Francisco Javier San Andrés-Rebollo; Carmen de Burgos-Lunar; Francisco Jesús Arrieta-Blanco; Paloma Gómez-Campelo Journal: PLoS One Date: 2013-10-17 Impact factor: 3.240